Savara Inc
NASDAQ:SVRA
Savara Inc
Interest Income Expense
Savara Inc
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Savara Inc
NASDAQ:SVRA
|
Interest Income Expense
$5.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
258%
|
CAGR 10-Years
54%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Interest Income Expense
-$2.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-7%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Income Expense
-$970m
|
CAGR 3-Years
16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-9%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Income Expense
-$3.3B
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
-18%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Income Expense
$558m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
124%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Income Expense
$773.4m
|
CAGR 3-Years
33%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
Savara Inc
Glance View
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Austin, Texas and currently employs 22 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the build-up of surfactant in the alveoli or air sacs of the lungs.
See Also
What is Savara Inc's Interest Income Expense?
Interest Income Expense
5.9m
USD
Based on the financial report for Sep 30, 2024, Savara Inc's Interest Income Expense amounts to 5.9m USD.
What is Savara Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
54%
Over the last year, the Interest Income Expense growth was 67%.
You don't have any saved screeners yet